Spectroscopy investment

News

LiteThru, a Warrington-based Science and Technology Facilities Council spinout, has secured £750,000 funding to commercialise its patented non-invasive analysis technology.

, a Warrington-based

(STFC) spinout, has secured £750,000 funding to commercialise its patented non-invasive analysis technology.

LiteThru’s developments use Raman spectroscopy in pharmaceutical analysis to look inside capsules or tablets and analyse their exact composition, at high speed and while still in the packaging. This could make production and quality control of medicines quicker, more accurate and cost-effective.

Pioneered at STFC’s Central Laser Facility, LiteThru’s technology uses a new form of spectroscopy, known as Spatially Offset Raman Spectroscopy (SORS), which enables the sensitive probing of objects such as capsules and tablets in blister packs or bottles without opening them. This concept is also being researched for its potential to diagnose breast cancer and detect bone disease non-invasively.

Dr Darren Andrews, chief executive at LiteThru Ltd, said: ‘This investment is the result of successful trials with several large pharmaceutical companies and will be used to build our first rapid analysis machines.

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox

Register
Or continue by

Signing in with your registered email address